On February 14, 2018, KEI meet with the FTC to express our opposition to Celgene’s proposed acquisition of Juno Therapeutics. Celgene-Juno-KEI-FTC16Feb2018 The Celgene acquisition of Juno Therapeutics would give Celgene control over competing candidates for the treatment of multiple myeloma… Continue Reading
On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading
PhRMA and BIO have both requested that the US Trade Representative place the European Union on its watch list in the 2018 Special 301 Report. The Special 301 Report is a yearly review by the US Trade Representative of the… Continue Reading
In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading
On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading
Attached is KEI’s February 8, 2018 submission to USTR, regarding the 2018 Special 301 list. Special301-KEI-Submission-8Feb2018 We also have all 29 years of Special 301 Reports, from 1989 to 2017, available here: https://keionline.org/ustr/special301
Knowledge Ecology International and 43 other health-care interested groups are calling on Congress to pass the CREATES Act. The CREATES Act, or the “Creating and Restoring Equal Access To Equivalent Samples Act of 2017”, is a bipartisan proposal to speed… Continue Reading
After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading
The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.8 on Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018 the either… Continue Reading
The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.7 on the Global strategy and plan of action on public health, innovation and intellectual property either on Wednesday, 24 January 2018 or Thursday, 25 January 2018.… Continue Reading